Fierce Healthcare

Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY® Supplemental New Drug Application for Use in Stress

N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Medscape

FDA Puts Boxed Warning on Echo Contrast Agents

October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

1 DEFINITY ® (Package Insert), North Billerica, MA, Lantheus Medical Imaging, Inc., 2017. 2 Parker JM, et al, Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.
Medscape

FDA approves new ultrasound contrast agent

Wilmington, DE -DuPont Pharmaceuticals announced today they have received FDA approval for their Definity? (Perflutren Lipid Microsphere) ultrasound contrast agent. Definity is used to improve the ...
Fox 5 San Diego

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...